These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34850039)

  • 1. Cell-Mediated Immune Responses After Administration of the Live or the Recombinant Zoster Vaccine: 5-Year Persistence.
    Johnson MJ; Liu C; Ghosh D; Lang N; Levin MJ; Weinberg A
    J Infect Dis; 2022 Apr; 225(8):1477-1481. PubMed ID: 34850039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Antibody Responses to the Live-Attenuated and Recombinant Herpes Zoster Vaccines.
    Schmid DS; Miao C; Leung J; Johnson M; Weinberg A; Levin MJ
    J Virol; 2021 May; 95(12):. PubMed ID: 33762414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of 5-Year Persistence of Antibody Responses to Zoster Vaccines.
    Weinberg A; Scott Schmid D; Leung J; Johnson MJ; Miao C; Levin MJ
    J Infect Dis; 2023 Nov; 228(10):1367-1374. PubMed ID: 37141390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Th1 memory differentiates recombinant from live herpes zoster vaccines.
    Levin MJ; Kroehl ME; Johnson MJ; Hammes A; Reinhold D; Lang N; Weinberg A
    J Clin Invest; 2018 Oct; 128(10):4429-4440. PubMed ID: 30024861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Immune Responses to Licensed Herpes Zoster Vaccines.
    Weinberg A; Kroehl ME; Johnson MJ; Hammes A; Reinhold D; Lang N; Levin MJ
    J Infect Dis; 2018 Sep; 218(suppl_2):S81-S87. PubMed ID: 30247596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity.
    Weinberg A; Pang L; Johnson MJ; Caldas Y; Cho A; Tovar-Salazar A; Canniff J; Schmader KE; Popmihajlov Z; Levin MJ
    J Virol; 2019 Aug; 93(15):. PubMed ID: 31092579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy.
    Lasagna A; Mele D; Bergami F; Alaimo D; Dauccia C; Alessio N; Comolli G; Pasi F; Muzzi A; Novelli V; Baldanti F; Pedrazzoli P; Cassaniti I
    Hum Vaccin Immunother; 2023 Dec; 19(3):2288282. PubMed ID: 38037900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune responses to zoster vaccines.
    Levin MJ; Weinberg A
    Hum Vaccin Immunother; 2019; 15(4):772-777. PubMed ID: 30676834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine.
    Dagnew AF; Klein NP; Hervé C; Kalema G; Di Paolo E; Peterson J; Salaun B; Schuind A
    J Infect Dis; 2021 Oct; 224(7):1139-1146. PubMed ID: 32103273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice.
    Stadtmauer EA; Sullivan KM; El Idrissi M; Salaun B; Alonso Alonso A; Andreadis C; Anttila VJ; Bloor AJ; Broady R; Cellini C; Cuneo A; Dagnew AF; Di Paolo E; Eom H; González-Rodríguez AP; Grigg A; Guenther A; Heineman TC; Jarque I; Kwak JY; Lucchesi A; Oostvogels L; Polo Zarzuela M; Schuind AE; Shea TC; Sinisalo UM; Vural F; Yáñez San Segundo L; Zachée P; Bastidas A
    Hum Vaccin Immunother; 2021 Nov; 17(11):4144-4154. PubMed ID: 34406911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient induction of cell-mediated immunity to varicella-zoster virus glycoprotein E co-lyophilized with a cationic liposome-based adjuvant in mice.
    Wui SR; Kim KS; Ryu JI; Ko A; Do HTT; Lee YJ; Kim HJ; Lim SJ; Park SA; Cho YJ; Kim CG; Lee NG
    Vaccine; 2019 Apr; 37(15):2131-2141. PubMed ID: 30827737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccines for preventing herpes zoster in older adults.
    Gagliardi AM; Andriolo BN; Torloni MR; Soares BG; de Oliveira Gomes J; Andriolo RB; Canteiro Cruz E
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31696946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Varicella-Zoster Virus-Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults.
    Weinberg A; Canniff J; Rouphael N; Mehta A; Mulligan M; Whitaker JA; Levin MJ
    J Immunol; 2017 Jul; 199(2):604-612. PubMed ID: 28607114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of glycoprotein E subunit and live attenuated varicella-zoster virus vaccines formulated with a single-strand RNA-based adjuvant.
    Lee SJ; Park HJ; Ko HL; Lee JE; Lee HJ; Kim H; Nam JH
    Immun Inflamm Dis; 2020 Jun; 8(2):216-227. PubMed ID: 32167678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Herpes Zoster Vaccines.
    Harbecke R; Cohen JI; Oxman MN
    J Infect Dis; 2021 Sep; 224(12 Suppl 2):S429-S442. PubMed ID: 34590136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial.
    Vink P; Ramon Torrell JM; Sanchez Fructuoso A; Kim SJ; Kim SI; Zaltzman J; Ortiz F; Campistol Plana JM; Fernandez Rodriguez AM; Rebollo Rodrigo H; Campins Marti M; Perez R; González Roncero FM; Kumar D; Chiang YJ; Doucette K; Pipeleers L; Agüera Morales ML; Rodriguez-Ferrero ML; Secchi A; McNeil SA; Campora L; Di Paolo E; El Idrissi M; López-Fauqued M; Salaun B; Heineman TC; Oostvogels L;
    Clin Infect Dis; 2020 Jan; 70(2):181-190. PubMed ID: 30843046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Varicella-zoster virus-specific cell-mediated immunity by interferon-γ Enzyme-Linked Immunosorbent Assay in adults ≥50 years of age administered a herpes zoster vaccine.
    Yang P; Chen Z; Zhang J; Li W; Zhu C; Qiu P; Quan Y; Cui X; Yuan L; Jiang C
    J Med Virol; 2019 May; 91(5):829-835. PubMed ID: 30613990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults.
    Levin MJ; Schmader KE; Pang L; Williams-Diaz A; Zerbe G; Canniff J; Johnson MJ; Caldas Y; Cho A; Lang N; Su SC; Parrino J; Popmihajlov Z; Weinberg A
    J Infect Dis; 2016 Jan; 213(1):14-22. PubMed ID: 26452397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials.
    López-Fauqued M; Co-van der Mee M; Bastidas A; Beukelaers P; Dagnew AF; Fernandez Garcia JJ; Schuind A; Tavares-da-Silva F
    Drug Saf; 2021 Jul; 44(7):811-823. PubMed ID: 34115324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Recombinant Herpes Zoster Vaccine for Primary Immunization of Varicella-seronegative Transplant Recipients.
    L'Huillier AG; Hirzel C; Ferreira VH; Ierullo M; Ku T; Selzner N; Schiff J; Juvet S; Miao C; Schmid DS; Humar A; Kumar D
    Transplantation; 2021 Oct; 105(10):2316-2323. PubMed ID: 33528118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.